Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,996 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum free light chains in a racially diverse population including African Americans and populations from South Africa.
Bertamini L, Alberge JB, Lee DJ, El-Khoury H, Kim S, Fleming G, Murphy CSM, Colchie J, Davis MI, Perry J, Lightbody ED, Allam S, Goqwana LN, Philip V, Smyth NA NA, Sakrikar D, Perkins MC, Harding S, Troske D, Getz G, Karlson EW, Munshi NC, Anderson KC, Trippa L, Marinac CR, Chen WC, Joffe M, Ghobrial IM. Bertamini L, et al. Among authors: perry j. Blood. 2024 Nov 21:blood.2024026078. doi: 10.1182/blood.2024026078. Online ahead of print. Blood. 2024. PMID: 39571144
Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population.
Lee DJ, El-Khoury H, Tramontano AC, Alberge JB, Perry J, Davis MI, Horowitz E, Redd R, Sakrikar D, Barnidge D, Perkins MC, Harding S, Mucci L, Rebbeck TR, Ghobrial IM, Marinac CR. Lee DJ, et al. Among authors: perry j. Blood Adv. 2024 Apr 9;8(7):1737-1746. doi: 10.1182/bloodadvances.2023010843. Blood Adv. 2024. PMID: 38212245 Free PMC article. Clinical Trial.
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
El-Khoury H, Lee DJ, Alberge JB, Redd R, Cea-Curry CJ, Perry J, Barr H, Murphy C, Sakrikar D, Barnidge D, Bustoros M, Leblebjian H, Cowan A, Davis MI, Amstutz J, Boehner CJ, Lightbody ED, Sklavenitis-Pistofidis R, Perkins MC, Harding S, Mo CC, Kapoor P, Mikhael J, Borrello IM, Fonseca R, Weiss ST, Karlson E, Trippa L, Rebbeck TR, Getz G, Marinac CR, Ghobrial IM. El-Khoury H, et al. Among authors: perry j. Lancet Haematol. 2022 May;9(5):e340-e349. doi: 10.1016/S2352-3026(22)00069-2. Epub 2022 Mar 25. Lancet Haematol. 2022. PMID: 35344689 Free PMC article.
Patient preferences for intervention in the setting of precursor multiple myeloma.
Marinac CR, Downey K, Perry J, Fisher-Longden B, Rebbeck TR, Shah UA, O'Donnell EK, Ghobrial IM, Nadeem O, Egleston BL. Marinac CR, et al. Among authors: perry j. Blood Cancer J. 2024 Oct 14;14(1):175. doi: 10.1038/s41408-024-01161-0. Blood Cancer J. 2024. PMID: 39402022 Free PMC article. No abstract available.
Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia.
Konishi Y, Sklavenitis-Pistofidis R, Yue H, Ferrari F, Redd RA, Lightbody ED, Russo M, Perry J, Horowitz E, Justis AV, Shayegh NA, Savell A, Prescott J, Varmeh S, Nowak RP, Hamilton M, Auclair D, Marinac CR, Trippa L, Fischer ES, Ghobrial IM. Konishi Y, et al. Among authors: perry j. Cancer Cell. 2022 Jan 10;40(1):6-8. doi: 10.1016/j.ccell.2021.12.003. Epub 2021 Dec 9. Cancer Cell. 2022. PMID: 34895486 Free PMC article. No abstract available.
MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology.
Dutta AK, Alberge JB, Lightbody ED, Boehner CJ, Dunford A, Sklavenitis-Pistofidis R, Mouhieddine TH, Cowan AN, Su NK, Horowitz EM, Barr H, Hevenor L, Beckwith JB, Perry J, Cao A, Lin Z, Kuhr FK, Mastro RGD, Nadeem O, Greipp PT, Stewart C, Auclair D, Getz G, Ghobrial IM. Dutta AK, et al. Among authors: perry j. Cancer Discov. 2023 Feb 6;13(2):348-363. doi: 10.1158/2159-8290.CD-22-0482. Cancer Discov. 2023. PMID: 36477267
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.
Cowan A, Ferrari F, Freeman SS, Redd R, El-Khoury H, Perry J, Patel V, Kaur P, Barr H, Lee DJ, Lightbody E, Downey K, Argyelan D, Theodorakakou F, Fotiou D, Liacos CI, Kanellias N, Chavda SJ, Ainley L, Sandecká V, Pospíšilová L, Minarik J, Jungova A, Radocha J, Spicka I, Nadeem O, Yong K, Hájek R, Kastritis E, Marinac CR, Dimopoulos MA, Get G, Trippa L, Ghobrial IM. Cowan A, et al. Among authors: perry j. Lancet Haematol. 2023 Mar;10(3):e203-e212. doi: 10.1016/S2352-3026(22)00386-6. Lancet Haematol. 2023. PMID: 36858677 Free PMC article.
CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias.
Fleming TJ, Antoszewski M, Lambo S, Gundry MC, Piussi R, Wahlster L, Shah S, Reed FE, Dong KD, Paulo JA, Gygi SP, Mimoso C, Goldman SR, Adelman K, Perry JA, Pikman Y, Stegmaier K, Barrachina MN, Machlus KR, Hovestadt V, Arruda A, Minden MD, Voit RA, Sankaran VG. Fleming TJ, et al. Among authors: perry ja. bioRxiv [Preprint]. 2024 Dec 30:2024.12.30.630680. doi: 10.1101/2024.12.30.630680. bioRxiv. 2024. PMID: 39803492 Free PMC article. Preprint.
A PI3Kδ-Foxo1-FasL signaling amplification loop rewires CD4 + T helper cell signaling, differentiation and epigenetic remodeling.
Golec DP, Gazzinelli-Guimaraes P, Chauss D, Nagashima H, Yu K, Hill T, Nivelo L, Cannons JL, Perry J, Joshi I, Pereira N, Oliveira FMS, Cruz AC, Druey KM, Lack JB, Nutman TB, Villarino AV, O'Shea JJ, Afzali B, Schwartzberg PL. Golec DP, et al. Among authors: perry j. bioRxiv [Preprint]. 2024 Nov 2:2024.10.28.620691. doi: 10.1101/2024.10.28.620691. bioRxiv. 2024. PMID: 39803425 Free PMC article. Preprint.
3,996 results